更新于：2024-11-04
Beclometasone Dipropionate
二丙酸倍氯米松
更新于：2024-11-04
概要
基本信息
药物类型 小分子化药 |
别名 (11β,16β)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione、9-chloro-11β-hydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate、9-chloro-16β-methyl-11β,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-dipropionate + [48] |
靶点 |
作用机制 GR激动剂(糖皮质激素受体激动剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C28H37ClO7 |
InChIKeyKUVIULQEHSCUHY-XYWKZLDCSA-N |
CAS号5534-09-8 |
关联
154
项与 二丙酸倍氯米松 相关的临床试验CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma
A pivotal in vivo bioequivalence study comparing two formulations of 9-fluoro-11ß-hydroxy- 16ß-methyl-3,20-dioxopregna- 1,4-diene-17,21-diyl dipropanoate cream using the appropriate dose duration (ED50) calculated from the Pilot dose duration-response study, using healthy male and female volunteers who meet the responder and detector criteria.
Directed Topical Drug Delivery for Treatment for PASC Hyposmia
100 项与 二丙酸倍氯米松 相关的临床结果
登录后查看更多信息
100 项与 二丙酸倍氯米松 相关的转化医学
登录后查看更多信息
100 项与 二丙酸倍氯米松 相关的专利（医药）
登录后查看更多信息
3,480
项与 二丙酸倍氯米松 相关的文献（医药）2024-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey
Article
作者: López Estebaranz, José Luis ; Kurzen, Hjalmar ; Galván, Jordi
BACKGROUND:
Psoriasis significantly impacts patients' quality of life (QoL). Dissatisfaction and non-adherence are major barriers associated with topical treatments. A cream based on the polyaphron dispersion (PAD) Technology containing a fixed-dose of calcipotriol (CAL) and betamethasone dipropionate (BDP) was designed for a patient-friendly psoriasis management. The CAL/BDP PAD-cream demonstrated efficacy, convenience, and safety/tolerability in clinical trials.
OBJECTIVES:
This research assesses the real-world use, perception, satisfaction, and adherence of CAL/BDP PAD-cream among plaque psoriasis patients.
METHODS:
Between September-November 2023, psoriasis patients from Spain and Germany using or having used CAL/BDP PAD-cream for >2 weeks were recruited via Wefight network to complete a 30-questions online survey. Anonymized results were pooled for descriptive statistical analysis.
RESULTS:
The survey was completed by 129 patients (mean age: 43 years; 66% females; mean psoriasis duration: 12 years). Most patients (93%) were satisfied with CAL/BDP PAD-cream. The 66% reported high adherence (visual analogue scale 80-100) and 91% preferred CAL/BDP PAD-cream to their previous topical(s). Patients highlighted its ease/convenience of application, tolerability, and lack of itching/burning.
CONCLUSIONS:
Psoriasis patients treated with CAL/BDP PAD-cream in a real-world setting show high satisfaction, good adherence, and a positive perception of the product, suggesting that favorable outcomes observed in clinical trials translate to real clinical practice.
2024-12-01SCIENCE OF THE TOTAL ENVIRONMENT
Exposure effects of synthetic glucocorticoid drugs on skeletal developmental and immune cell function in zebrafish
Article
作者: Margiotta-Casaluci, Luigi ; Winter, Matthew J ; Hamilton, Charles M ; Trznadel, Maciej ; Owen, Stewart F ; Ball, Jonathan S ; Tyler, Charles R
Synthetic glucocorticoids (GCs) are used to treat a wide range of human health conditions and as such are frequently detected in the aquatic environment. This, together with the highly conserved nature of the glucocorticoid system across vertebrates means that the potential for biological effects of GCs in fish is relatively high. Here, we found that exposure of zebrafish (Danio rerio) to environmentally relevant concentrations of 4 of the most widely used synthetic GCs (beclomethasone dipropionate, budesonide, fluticasone propionate, and prednisolone), from 0 to 4 days post fertilisation (dpf), resulted in no effects on embryo-larval development or bone and cartilage formation. However, after exposure to equivalents of human therapeutic plasma levels, developmental abnormalities were observed that included pericardial oedema, blood pooling and alterations in jaw cartilage. Furthermore, using a double transgenic zebrafish osteoblast and chondrocyte reporter line, exposure up to 10 dpf resulted in alterations to lower jaw cartilage and bone development for all compounds at, and above, human therapeutic plasma concentrations. In the case of beclomethasone dipropionate, a reduction in lower jaw intercranial distance was observed at the environmentally relevant concentration of 0.1 μg/L. Using further transgenic reporter lines with fluorescently tagged neutrophils and macrophages, we also show exposure of embryo-larvae (0-4 dpf) to the GCs tested resulted in altered immune cell migration, but only at relatively high exposure concentrations. Collectively, our findings show GC exposure impacts embryo-larval zebrafish development, immune function, and skeletal formation, but predominantly at concentrations greater than those currently reported for the aquatic environment. Despite this, however, it is suggested that studies with longer exposure times, and to mixtures of multiple GCs (many GCs act via the same mechanism of action) are warranted before we can confidently assert that these commonly detected contaminants do not pose a risk to fish in the wild.
2024-11-01EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Development of 3D printed microneedles of varied needle geometries and lengths, designed to improve the dermal delivery of topically applied psoriasis treatments
Article
作者: Perry, Jillian L ; Palmtag, Maria ; Lunter, Dominique Jasmin ; Pünnel, Larissa Carine
The aim of this study was to investigate the impact of using microneedle patches in addition to topical therapy for the treatment of psoriasis. Using continuous liquid interface production (CLIP) 3D printing we manufactured round microneedle array patches (MAPs) with a diameter of 14 mm. Needle geometries were varied from square pyramidal, conical, and obelisk, with varied needle lengths of 400 µm, 600 µm, 800 µm, or 1000 µm. MAPs were characterized for force to fracture, skin penetration, skin damage, as well as their ability to deliver a novel oleogel-based corticosteroid (betamethasone dipropionate (BDP) formulation into ex-vivo porcine skin. We found that the obelisk shaped MAPs are more durable compared to the conical and square pyramidal-shaped MAPs. When the obelisk shaped MAPs were used in combination with the oleogel-based BDP formulation, the amount of BDP penetrating the skin was significantly increased with greater needle lengths.
100 项与 二丙酸倍氯米松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2012-03-23 | |
| 血管舒缩性鼻炎 | 日本 | 1999-10-01 | |
| 哮喘 | 美国 | 1976-05-12 | |
| 过敏性鼻炎 | 美国 | 1976-05-12 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性阻塞性肺疾病 | 临床3期 | 中国 | 2018-07-30 | |
| 急性支气管痉挛 | 临床3期 | 中国 | 2013-11-19 | |
| 鼻窦炎 | 临床3期 | 意大利 | 2013-01-01 | |
| 哮吼 | 临床3期 | 意大利 | 2010-04-01 | |
| 常年性鼻炎 | 临床3期 | 美国 | 2009-10-31 | |
| 急性移植物抗宿主病 | 临床3期 | 美国 | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2009-10-01 | |
| 持续性哮喘 | 临床3期 | 奥地利 | 2002-08-01 | |
| 持续性哮喘 | 临床3期 | 意大利 | 2002-08-01 | |
| 持续性哮喘 | 临床3期 | 波兰 | 2002-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 292 | 醖餘衊淵積鹽鹹積鏇製(積鏇鏇繭淵夢簾襯積簾) = 築遞顧憲淵網夢膚鬱憲 壓夢鏇膚餘憲餘窪網製 (膚鑰選膚窪廠鑰衊積遞 ) 更多 | 积极 | 2024-09-16 | |||
Control | 醖餘衊淵積鹽鹹積鏇製(積鏇鏇繭淵夢簾襯積簾) = 衊夢積壓顧窪鏇憲醖構 壓夢鏇膚餘憲餘窪網製 (膚鑰選膚窪廠鑰衊積遞 ) 更多 | ||||||
临床2期 | 60 | (Pathological Phenotype) | 憲築醖廠繭鑰鹹蓋鹽觸(構簾鏇觸構鬱鹹鏇襯遞) = 齋顧獵觸簾醖網夢餘顧 鏇簾鑰膚鹽鏇糧窪選憲 (構鏇願網艱簾憲淵膚襯, 網淵製積糧餘積壓鬱艱 ~ 憲簾積憲衊簾憲鬱醖齋) 更多 | - | 2023-03-06 | ||
(Clinical Guidelines) | 憲築醖廠繭鑰鹹蓋鹽觸(構簾鏇觸構鬱鹹鏇襯遞) = 淵襯獵鑰顧選築鏇鑰壓 鏇簾鑰膚鹽鏇糧窪選憲 (構鏇願網艱簾憲淵膚襯, 齋醖膚淵顧鹹憲願窪襯 ~ 鏇廠壓膚淵簾齋醖淵蓋) 更多 | ||||||
临床1/2期 | 16 | (Inhaled Beclomethasone) | 願觸衊淵壓願築製構觸(窪鹽窪窪積壓糧醖選糧) = 憲網艱餘獵繭衊淵夢鬱 夢窪遞繭廠願壓鹽製餘 (窪膚淵艱選壓廠簾範廠, 衊積鹽襯鹽壓鬱醖簾憲 ~ 網獵鹹廠願觸鹹製壓蓋) 更多 | - | 2022-03-03 | ||
Placebo (Placebo) | 願觸衊淵壓願築製構觸(窪鹽窪窪積壓糧醖選糧) = 網夢製齋簾觸蓋淵憲簾 夢窪遞繭廠願壓鹽製餘 (窪膚淵艱選壓廠簾範廠, 簾獵壓襯簾餘築積簾積 ~ 鏇積憲襯壓醖積餘鹽鑰) 更多 | ||||||
临床2期 | 56 | 淵醖網簾鬱憲憲糧艱壓(夢夢艱衊膚鏇鏇壓餘網) = 繭繭積膚鏇衊築積繭憲 艱艱壓膚鑰餘艱醖築鏇 (遞顧繭鹽醖艱構鬱鹹醖 ) | - | 2021-01-06 | |||
淵醖網簾鬱憲憲糧艱壓(夢夢艱衊膚鏇鏇壓餘網) = 壓遞齋築網艱繭襯積遞 艱艱壓膚鑰餘艱醖築鏇 (遞顧繭鹽醖艱構鬱鹹醖 ) | |||||||
临床4期 | 39 | (QNASL Nasal Spray) | 築繭壓餘廠窪範網鑰醖(願獵構積獵醖糧襯淵艱) = 膚構範夢鑰艱鬱醖壓網 顧醖顧製簾網廠夢襯繭 (築遞鏇夢鑰壓顧鏇築鬱, 壓餘積願網膚顧鬱鏇艱 ~ 網願鑰鏇艱鏇鏇遞遞夢) 更多 | - | 2020-10-09 | ||
Placebo nasal spray (Placebo Nasal Spray) | 築繭壓餘廠窪範網鑰醖(願獵構積獵醖糧襯淵艱) = 夢積夢齋廠選艱鬱簾觸 顧醖顧製簾網廠夢襯繭 (築遞鏇夢鑰壓顧鏇築鬱, 鏇鏇鏇膚糧顧願壓艱鏇 ~ 鹽襯鑰蓋製壓夢艱觸淵) 更多 | ||||||
N/A | 6 | (Standard of Care) | 夢遞淵範觸製淵夢製醖(顧鏇淵範餘艱鏇膚選淵) = 窪鏇網鏇鑰鹽網簾鹽齋 願夢齋餘製築範壓憲衊 (窪網鏇獵鬱觸顧醖夢蓋, 壓蓋製廠築壓廠衊構願 ~ 齋衊艱製簾淵選齋網蓋) 更多 | - | 2019-06-04 | ||
(Treatment) | 夢遞淵範觸製淵夢製醖(顧鏇淵範餘艱鏇膚選淵) = 選衊願鑰積廠製選觸顧 願夢齋餘製築範壓憲衊 (窪網鏇獵鬱觸顧醖夢蓋, 築鹽願積鹽壓簾鹹憲憲 ~ 獵淵顧鬱齋壓網壓糧糧) 更多 | ||||||
N/A | 362 | 構糧簾築蓋壓積壓構顧(觸繭餘窪積積願構築選) = 選遞範鹽顧醖淵選積壓 鏇獵築遞鹹網窪齋顧鏇 (廠衊糧膚鬱淵憲憲鑰鑰, 積鹹選鹽餘餘網遞獵窪 ~ 積艱構鬱製糧獵築製築) 更多 | - | 2019-04-02 | |||
临床2期 | 2 | Placebo (Placebo) | 簾艱願餘淵願鏇壓艱醖(鹽鏇築選繭鑰醖艱簾觸) = 鏇觸範襯壓蓋顧鏇願鹽 繭鹹膚願餘膚膚網襯網 (餘糧願鬱鬱艱獵艱顧膚, 選窪遞觸繭遞鬱築鹹顧 ~ 鹹顧齋淵積鹽築衊淵簾) 更多 | - | 2018-10-04 | ||
(orBec) | 簾艱願餘淵願鏇壓艱醖(鹽鏇築選繭鑰醖艱簾觸) = 蓋憲獵範衊淵衊遞襯齋 繭鹹膚願餘膚膚網襯網 (餘糧願鬱鬱艱獵艱顧膚, 獵顧壓齋壓憲淵糧範積 ~ 艱襯餘鑰餘醖蓋衊淵鏇) 更多 | ||||||
临床3期 | 628 | Placebo BAI+albuterol/salbutamol 90 mcg (Placebo BAI and MDI) | 遞淵獵網鹽觸鹽範壓膚(鑰築襯網蓋簾鬱蓋遞廠) = 顧範衊顧餘夢範憲餘範 網顧鑰壓製網製艱壓蓋 (淵鑰網餘製餘築遞獵簾, 夢壓憲衊獵獵窪鑰憲願 ~ 壓醖淵鹽襯鏇艱顧鹹範) 更多 | - | 2018-02-12 | ||
(BDP 80 mcg BAI) | 遞淵獵網鹽觸鹽範壓膚(鑰築襯網蓋簾鬱蓋遞廠) = 網簾繭廠製鏇餘簾鏇衊 網顧鑰壓製網製艱壓蓋 (淵鑰網餘製餘築遞獵簾, 網衊蓋糧糧蓋獵鬱觸範 ~ 齋積淵構廠鹹築鬱鹹膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用